Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label phase II study assessing the activity of cabozantinib combined with
atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are
ineligible for cisplatin-based therapy or decline cisplatin-based therapy. Each cycle equals
21 days. The dose of atezolizumab is 1200 mg IV flat dose every 3 weeks (Day 1) plus
cabozantinib 40 mg orally daily (Day 1 through Day 21). Patients will receive three cycles of
treatment prior to cystectomy unless they discontinue treatment for unacceptable toxicity or
progressive disease by RECIST v1.1 or withdraw consent.
Phase:
Phase 2
Details
Lead Sponsor:
Deepak Kilari
Collaborators:
Exelixis Genentech, Inc. Medical College of Wisconsin